top of page

ASX: IMU - Imugene

Imugene: A worldwide license to attack blood cancer


Imugene Managing Director Leslie Chong on 3AW, 2GB, 4BC & 6PR Bulls N' Bears Report


Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s rapidly developing stable of extraordinary cancer-fighting treatments that now take in blood cancers in addition to solid tumours.



TO LISTEN TO THE IMUGENE AUDIO INTERVIEW - CLICK BELOW


Imugene is a clinical-stage immunotherapy company developing a range of new treatments that seek to activate and strengthen a patient's own immune system to identify and ultimately eradicate cancerous tumours. The company has just entered into an agreement with NASDAQ-listed biotech company Precision Biosciences to acquire a license for its azer-cel treatment for people with blood cancers.



Comments


bottom of page